Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.
Christelle Ferrá(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), María-Luisa Bordejé(Hospital Universitari Germans Trias i Pujol), Maite Misis(Hospital Universitari Germans Trias i Pujol), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Albert Oriol(Institut Català d'Oncologia), Javier Grau, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Montserrat Batlle(Centro de Investigación en Red en Enfermedades Cardiovasculares), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Jordi Klamburg(Hospital Universitari Germans Trias i Pujol), Natàlia Lloveras, Alonso Flores, Evarist Feliú(Universitat Autònoma de Barcelona)
Cited by 0
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719